---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-24-000013"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:41:56.936655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics enters collaboration with SAKK for Phase 2 breast cancer study of INT230-6

## Summary
- SAKK to conduct Phase 2 of INVINCIBLE-4 Study testing INT230-6 plus standard of care vs standard of care alone in neoadjuvant triple negative breast cancer in Europe.
- Intensity will supply INT230-6 and provide up to approximately $3.0 million in funding for the study.
- Indemnification: SAKK indemnifies Intensity for claims from its study duties; Intensity indemnifies SAKK for issues from drug manufacturing, packaging, labeling.
- Term runs until final clinical study report; either party may terminate for material breach, negligible scientific value, safety, or significant recruitment delay (>12 months).

## SEC filing metadata
- accession: 0001567264-24-000013
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/0001567264-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/intensity-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-24-000013
- JSON: https://secwatch.observer/filing/0001567264-24-000013.json
- Plain text: https://secwatch.observer/filing/0001567264-24-000013.txt

## Key facts
- Material Agreements
  INTENSITY THERAPEUTICS, INC. entered into Collaboration Agreement with The Swiss Group for Cancer Research SAKK valued at funding in the amount of up to approximately $3.0 million (effective 2024-05-06).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: The Swiss Group for Cancer Research SAKK
  - Value: funding in the amount of up to approximately $3.0 million
  - Effective: 2024-05-06
  source text: On May 6, 2024, Intensity Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with The Swiss Group for Cancer Research SAKK (“SAKK”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/0001567264-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.